231 related articles for article (PubMed ID: 26202613)
21. Chronic cannabinoid exposure produces tolerance to the dopamine releasing effects of WIN 55,212-2 and heroin in adult male rats.
Gomez DM; Everett TJ; Hamilton LR; Ranganath A; Cheer JF; Oleson EB
Neuropharmacology; 2021 Jan; 182():108374. PubMed ID: 33115642
[TBL] [Abstract][Full Text] [Related]
22. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development.
De Vry J; Jentzsch KR; Kuhl E; Eckel G
Behav Pharmacol; 2004 Feb; 15(1):1-12. PubMed ID: 15075621
[TBL] [Abstract][Full Text] [Related]
23. The effect of chronic opioid vs. cannabinoid exposure on the expression of tolerance to morphine- or WIN-55,212-2-induced analgesia and hypothermia in the guinea pig.
Maguma H; Taylor DA
Eur J Pharmacol; 2011 Jun; 660(2-3):334-40. PubMed ID: 21514292
[TBL] [Abstract][Full Text] [Related]
24. c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner.
Henderson-Redmond AN; Nealon CM; Davis BJ; Yuill MB; Sepulveda DE; Blanton HL; Piscura MK; Zee ML; Haskins CP; Marcus DJ; Mackie K; Guindon J; Morgan DJ
Neuropharmacology; 2020 Mar; 164():107847. PubMed ID: 31758947
[TBL] [Abstract][Full Text] [Related]
25. The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.
Hruba L; McMahon LR
Eur J Pharmacol; 2014 Mar; 727():35-42. PubMed ID: 24486701
[TBL] [Abstract][Full Text] [Related]
26. Contribution of spinal 5-HT
Aksu AG; Gunduz O; Ulugol A
Can J Physiol Pharmacol; 2018 Jun; 96(6):618-623. PubMed ID: 29406831
[TBL] [Abstract][Full Text] [Related]
27. Reduction in opioid- and cannabinoid-induced antinociception in rhesus monkeys after bilateral lesions of the amygdaloid complex.
Manning BH; Merin NM; Meng ID; Amaral DG
J Neurosci; 2001 Oct; 21(20):8238-46. PubMed ID: 11588195
[TBL] [Abstract][Full Text] [Related]
28. Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl.
Maguire DR; France CP
Eur J Pharmacol; 2016 Aug; 784():199-206. PubMed ID: 27184925
[TBL] [Abstract][Full Text] [Related]
29. Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids.
Barrett AC; Cook CD; Terner JM; Craft RM; Picker MJ
Psychopharmacology (Berl); 2001 Nov; 158(2):154-64. PubMed ID: 11702089
[TBL] [Abstract][Full Text] [Related]
30. Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats.
Walker EA; Young AM
Psychopharmacology (Berl); 2001 Mar; 154(2):131-42. PubMed ID: 11314675
[TBL] [Abstract][Full Text] [Related]
31. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
32. Pronociceptive effects of spinal dynorphin promote cannabinoid-induced pain and antinociceptive tolerance.
Gardell LR; Burgess SE; Dogrul A; Ossipov MH; Malan TP; Lai J; Porreca F
Pain; 2002 Jul; 98(1-2):79-88. PubMed ID: 12098619
[TBL] [Abstract][Full Text] [Related]
33. Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio.
Maguire DR; France CP
Eur J Pharmacol; 2018 Jan; 819():217-224. PubMed ID: 29183835
[TBL] [Abstract][Full Text] [Related]
34. Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception.
Wilson AR; Maher L; Morgan MM
Neuropharmacology; 2008 Dec; 55(7):1219-25. PubMed ID: 18723035
[TBL] [Abstract][Full Text] [Related]
35. Effects of the synthetic cannabinoid receptor agonist JWH-018 on abuse-related effects of opioids in rhesus monkeys.
Gerak LR; Weed PF; Maguire DR; France CP
Drug Alcohol Depend; 2019 Sep; 202():33-38. PubMed ID: 31295696
[TBL] [Abstract][Full Text] [Related]
36. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
Pertwee RG; Stevenson LA; Griffin G
Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
[TBL] [Abstract][Full Text] [Related]
37. Antinociceptive effects of cocaine in rhesus monkeys.
Gatch MB; Negus SS; Mello NK
Pharmacol Biochem Behav; 1999 Feb; 62(2):291-7. PubMed ID: 9972696
[TBL] [Abstract][Full Text] [Related]
38. Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice.
Chopda GR; Parge V; Thakur GA; Gatley SJ; Makriyannis A; Paronis CA
J Pharmacol Exp Ther; 2016 Aug; 358(2):334-41. PubMed ID: 27231154
[TBL] [Abstract][Full Text] [Related]
39. Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.
Fan F; Compton DR; Ward S; Melvin L; Martin BR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1383-90. PubMed ID: 7996450
[TBL] [Abstract][Full Text] [Related]
40. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
Tham SM; Angus JA; Tudor EM; Wright CE
Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
